Literature DB >> 1033072

Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats.

P H Kelly, S D Iversen.   

Abstract

Selective large scale destruction of mesolimbic dopamine-containing terminals is produced by bilateral injection of 8 mug of 6-hydroxydopamine (6OHDA) into the nucleus accumbens septi (NAS) of rats pretreated with pargyline and desipramine (DMI). The DMI prevents the destruction of the noradrenergic innervation of the forebrain normally produced by the NAS 6OHDA lesion, without affecting the destruction of dopamine-containing neurons. The locomotor stimulation produced by the psychostimulants d-amphetamine (1.5 mg/kg) and cocaine (20 mg/kg) is blocked in rats with selective destruction of the mesolimbic dopamine system. In contrast the locomotor stimulation produced by the directly acting dopamine agonist apomorphine (1.0 mg/kg) is enhanced, which may indicate supersensitivity of the denervated dopamine receptors. These results lend further support to the view that psychostimulant-induced locomotr stimulation in rats results from effects on mesolimbic dopamine neurons. In addition, the protection by DMI of noradrenergic neurons from the toxic effects of 6OHDA is evidence that 6OHDA, as used here, destroys catecholamine neurons mainly by an uptake-dependent specific mechanism.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1033072     DOI: 10.1016/0014-2999(76)90352-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  121 in total

1.  Involvement of 5-HT(3) receptors in the nucleus accumbens in the potentiation of cocaine-induced behaviours in the rat.

Authors:  S Herges; D A Taylor
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Blockade of substantia nigra dopamine D1 receptors reduces intravenous cocaine reward in rats.

Authors:  Matthew G Quinlan; Ruth Sharf; David Y Lee; Roy A Wise; Robert Ranaldi
Journal:  Psychopharmacology (Berl)       Date:  2004-02-07       Impact factor: 4.530

3.  Stimulation of protein-tyrosine phosphorylation in rat striatum after lesion of dopamine neurons or chronic neuroleptic treatment.

Authors:  J A Girault; J C Siciliano; L Robel; D Hervé
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

4.  Dopamine and conditioned reinforcement. I. Differential effects of amphetamine microinjections into striatal subregions.

Authors:  A E Kelley; J M Delfs
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 5.  Drug-sensitive reward in crayfish: an invertebrate model system for the study of SEEKING, reward, addiction, and withdrawal.

Authors:  Robert Huber; Jules B Panksepp; Thomas Nathaniel; Antonio Alcaro; Jaak Panksepp
Journal:  Neurosci Biobehav Rev       Date:  2010-12-21       Impact factor: 8.989

6.  The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine.

Authors:  W A Corrigall; K B Franklin; K M Coen; P B Clarke
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Stimulation of D2 receptors in the prefrontal cortex reduces PCP-induced hyperactivity, acetylcholine release and dopamine metabolism in the nucleus accumbens.

Authors:  A Del Arco; F Mora; A H Mohammed; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

Review 8.  The role of cognitive control in cocaine dependence.

Authors:  Hugh Garavan; Robert Hester
Journal:  Neuropsychol Rev       Date:  2007-08-07       Impact factor: 7.444

9.  Increased phasic dopamine signaling in the mesolimbic pathway during social defeat in rats.

Authors:  K K Anstrom; K A Miczek; E A Budygin
Journal:  Neuroscience       Date:  2009-03-17       Impact factor: 3.590

Review 10.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.